摘要
目的 探究临床治疗手足口病时应用α2b(重组干扰素)的价值。方法研究共有受试者60例,均选取自我院感染科,选取时间为2021年2月到2022年3月,将所有受试对象进行随机分组,分成研究组、对照组,每组平均30人,组内应用不同的治疗方法,比对最终疗效和病人疼痛指数变化。结果研究组手足口病人治疗显效和有效例数之和为28例,总有效率明显更高,P<0.05;治疗前,组间口腔疼痛程度差异小;治疗后,2组疼痛程度评分均降低,但研究组评分明显更低,研究数据排除治疗前和治疗后1天,其余数值对比均为P<0.05;治疗后,2组手足口病患儿症状均有所好转,研究组内小儿高热、疱疹和皮疹等症状消退时间更快,总住院时长更短,P<0.05。结论 针对手足口病α2b(重组干扰素)的临床药效显著,治疗后患儿疼痛指数逐渐降低,适合积极推广。
关键词: 重组干扰素;α2b;手足口病;治疗价值
Abstract
Objective: To explore the clinical application in the treatment of hand, foot and mouth disease α Value of 2B (recombinant interferon). Methods: a total of 60 subjects were selected from the Department of nosocomial infection from February 2021 to March 2022. All subjects were randomly divided into study group and control group, with an average of 30 people in each group. Different treatment methods were used in the group to compare the final therapeutic effect and the change of patient pain index. Results: in the study group, the total effective rate was significantly higher (P; Before treatment, there was little difference in the degree of oral pain between groups; After treatment, the pain scores of the two groups decreased, but the scores of the study group were significantly lower. The study data excluded the pre-treatment and 1 day after treatment, and the other values were compared (P < 0.05).;After treatment, the symptoms of both children with HFMD improved. In the study group, symptoms with high fever, herpes and rash subsided faster and the total hospitalization was shorter, P <0.05.Conclusion : for HFMD α The clinical efficacy of 2B (recombinant interferon) is significant, and the pain index of children gradually decreases after treatment, which is suitable for active promotion.
Key words: Recombinant Interferon; α 2B; Hand foot Mouth Disease; Therapeutic Value
参考文献 References
[1] 李懿,郝建华,王芳,周莉,巩冬艳,申远方,冯晓靖,许汴利,黄学勇.重组人干扰素α2b喷雾剂治疗小儿手足口病轻症的效果评价[J].河南医学研究,2021, 30(20): 3667-3670.
[2] 高楠,岳瑾,李淑娟,胡蓉,张玲.重组人干扰素α-2b雾化治疗小儿手足口病的效果分析[J].中国临床实用医学,2021,12(03):52-56.
[3] 孙玲玲.人免疫球蛋白与重组人干扰素α-2b治手足口病效果[J].中国城乡企业卫生,2021,36(05):116-118.
[4] 赵珊,吴玉卓.重组人干扰素α-2b联合利巴韦林对手足口病患儿的疗效[J].河南医学研究,2021,30(05):914-916.
[5] 魏农,陈至立,丁宁.重组人干扰素α2b联合治疗手足口病患儿的临床研究[J].中国临床药理学杂志,2020,36(23):3884-3887.
[6] 陈洁婉.手足口病治疗中重组干扰素的治疗效果探讨[J].临床研究,2020,28(12):36-38.
[7] 许琼,邓菊花,庞金凤,李小丽.磷酸奥司他韦颗粒联合小儿豉翘清热颗粒、人干扰素α2b治疗小儿手足口病的临床疗效及其对患儿肝功能的影响[J].临床合理用药杂志,2022,15(30):126-129.
[8] 王应云,张利果.小儿双清颗粒联合重组人干扰素α2b治疗儿童手足口病的临床研究[J].现代药物与临床,2020,35(07):1438-1441.
[9] 王团结,肖爱菊,徐玉萍,刘炜青,任瑞娟,李树军.重组人干扰素α2b治疗重症手足口病患儿的临床研究[J].罕少疾病杂志,2020,27(04):88-89.
[10] 黄云,樊晓艳.重组人干扰素α2b雾化吸入治疗小儿手足口病的临床分析[J].泰州职业技术学院学报,2020, 20(Z1): 117-119.
[11] 唐晓芳,童晓玲,安阳阳.重组人干扰素α2b喷雾剂和利巴韦林喷雾剂治疗小儿手足口病的效果比较[J].川北医学院学报,2020,35(02):294-296.
[12] 谭丽琴,韩玉兰,周林英,韦冰梅.重组人干扰素α2b雾化联合金振口服液治疗手足口病的疗效分析[J].河北医药,2020,42(06):917-919.